Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Low-dose aspirin use and risk of head and neck cancer-A Danish nationwide case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Drug-drug interaction between warfarin and statins: A Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Endometrial cancer risk after fertility treatment: a population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. TORS Base-of-Tongue Mucosectomy in Human Papilloma Virus-Negative Carcinoma of Unknown Primary

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Results concerning a potential preventive effect of aspirin on head and neck cancer (HNC) are conflicting. We examined the association between low-dose aspirin use and HNC risk overall and by degree of human papillomavirus association in a nested case-control study using nationwide registries. Cases (n = 12 389) were all Danish residents diagnosed with primary HNC (2000-2015). Age- and sex-matched population controls (n = 185 835) were selected by risk-set-sampling. Using conditional logistic regression, we estimated multivariable-adjusted odds ratios and 95% confidence intervals for HNC associated with low-dose aspirin use (≥2 prescriptions). No association was observed between low-dose aspirin ever-use and overall HNC (odds ratio: 1.03, 95% confidence interval: 0.97-1.10). Estimates remained neutral according to patterns of use. Low-dose aspirin use appeared to slightly decrease HNC risk among the eldest (71-84 y), independently of human papillomavirus association, while slightly increase HNC risk among younger age groups (30-60, 61-70 y), driven by an increased risk of oral cancer. However, no consistent patterns in risk estimates were found according to duration and consistency of low-dose aspirin use in the age-stratified analyses.

OriginalsprogEngelsk
TidsskriftBritish Journal of Clinical Pharmacology
ISSN0306-5251
DOI
StatusE-pub ahead of print - 31 jul. 2020

Bibliografisk note

© 2020 The British Pharmacological Society.

ID: 60788825